Diabetic Kidney Disease Overview

Diabetic Kidney Disease (DKD), also known as Diabetic nephropathy is a chronic, progressive disease that develops overtime. Diabetic nephropathy is a major long-term complication affecting approximately 30% of patients with type 1 diabetes (T1D) and 40% of those with type 2 diabetes (T2D). DKD is also associated with a high mortality rate.

“Diabetic Kidney Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diabetic Kidney Disease Market.

The Diabetic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Diabetic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diabetic Kidney Disease treatment therapies with a considerable amount of success over the years. Diabetic Kidney Disease Key players such as – Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, Dimerix Bioscience Pty Ltd., Eli Lilly and Company, Inversago Pharma Inc., Gilead Sciences, Bayer, Serodus ASA, AstraZeneca, Sanwa Kagaku Kenkyusho Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and others, are developing therapies for the Diabetic Kidney Disease treatment 
• Diabetic Kidney Disease Emerging therapies such as – ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, Propagermanium, Baricitinib, INV-202, Selonsertib, Fulacimstat (BAY1142524), SER150, Dapagliflozin, Topiroxostat BID, MT-3995, and others are expected to have a significant impact on the Diabetic Kidney Disease market in the coming years.   
• In May 2018, Kyowa Kirin Co., Ltd. initiated a Phase III randomized, double-blind, placebo-controlled clinical trial in patients with Diabetic Kidney Disease
• Finerenone (BAY94–8862) by Bayer, which is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. It blocks the detrimental effects due to over activation of the receptor by aldosterone and cortisol, which increases blood pressure and has been implicated in a number of other deleterious effects in the kidney, vasculature, and heart. The drug is in phase III stage of clinical development for Diabetic Kidney Disease

Diabetic Kidney Disease Pipeline Therapeutics Assessment

• Diabetic Kidney Disease Assessment by Product Type
• Diabetic Kidney Disease By Stage and Product Type
• Diabetic Kidney Disease Assessment by Route of Administration
• Diabetic Kidney Disease By Stage and Route of Administration
• Diabetic Kidney Disease Assessment by Molecule Type
• Diabetic Kidney Disease by Stage and Molecule Type

DelveInsight’s Diabetic Kidney Disease Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Diabetic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Diabetic Kidney Disease are – Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Teijin America, Boehringer Ingelheim, Eli Lilly and Company, Chinook Therapeutics, Abbvie, Mitsubishi Tanabe Pharma, CSL Behring, Gilead Sciences, Goldfinch Bio, Novartis Pharmaceuticals, Prokidney, and others.

Emerging Diabetic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

• ORBCEL-M: Orbsen Therapeutics
• DMX-200: Dimerix Bioscience
• INV-202: Inversago Pharma
• CSL346: CSL Behring
• Bardoxolone methyl: Kyowa kirin
• Propagermanium: Dimerix Bioscience Pty Ltd
• Baricitinib: Eli Lilly and Company
• INV-202: Inversago Pharma Inc.
• Selonsertib: Gilead Sciences
• Fulacimstat (BAY1142524): Bayer
• SER150: Serodus ASA
• Dapagliflozin: AstraZeneca
• Topiroxostat BID: Sanwa Kagaku Kenkyusho Co., Ltd. MT-3995: Mitsubishi Tanabe Pharma Corporation

Get a Free Sample PDF Report to know more about Diabetic Kidney Disease Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/diabetic-kidney-disease-dkd-pipeline-insight

Diabetic Kidney Disease Pipeline Analysis:

The Diabetic Kidney Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Diabetic Kidney Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diabetic Kidney Disease Treatment.
• Diabetic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diabetic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diabetic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Diabetic Kidney Disease product details are provided in the report. Download the Diabetic Kidney Disease pipeline report to learn more about the emerging Diabetic Kidney Disease therapies

Diabetic Kidney Disease Pipeline Market Drivers

• Increasing prevalence of diabetes worldwide
• Rising geriatric population
• Increasing demand of novel therapies

Diabetic Kidney Disease Pipeline Market Barriers

• Lack of skilled professionals to treat diabetic kidney disease in less developed countries
• Stringent regulatory guidelines

Scope of Diabetic Kidney Disease Pipeline Drug Insight    

• Coverage: Global
• Key Diabetic Kidney Disease Companies: Orbsen Therapeutics, Dimerix Bioscience, Inversago Pharma, CSL Behring, Kyowa kirin, Dimerix Bioscience Pty Ltd., Eli Lilly and Company, Inversago Pharma Inc., Gilead Sciences, Bayer, Serodus ASA, AstraZeneca, Sanwa Kagaku Kenkyusho Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and others
• Key Diabetic Kidney Disease Therapies: ORBCEL-M, DMX-200, INV-202, CSL346, Bardoxolone methyl, Propagermanium, Baricitinib, INV-202, Selonsertib, Fulacimstat (BAY1142524), SER150, Dapagliflozin, Topiroxostat BID, MT-3995, and others
• Diabetic Kidney Disease Therapeutic Assessment: Diabetic Kidney Disease current marketed and Diabetic Kidney Disease emerging therapies
• Diabetic Kidney Disease Market Dynamics: Diabetic Kidney Disease market drivers and Diabetic Kidney Disease market barriers 

Request for Sample PDF Report for Diabetic Kidney Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Diabetic Kidney Disease drugs and therapies

Related Reports by DelveInsight- 

scedosporium infection market | autoimmune pulmonary alveolar proteinosis market | rosai-dorfman disease market | sandhoff disease market | b-cell chronic lymphocytic leukemia market | bladder cancer market | trichomoniasis market | bile duct cancer market | resorbable vascular scaffold market | salivary gland infection market | ischemic stroke market | paget’s disease market | ventricular assist devices market | vascular stents market | vascular graft devices market | bladder scanners market | b-cell non-hodgkin lymphoma market | basal cell carcinoma market | birch allergy market | vein illumination devices market

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting